Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1921 to 1925 of 1925 entries
Sorted by: Best Match Show Resources per page
Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis.

EBioMedicine

Martínez-Bosch N, Cristóbal H, Iglesias M, Gironella M, Barranco L, Visa L, Calafato D, Jiménez-Parrado S, Earl J, Carrato A, Manero-Rupérez N, Moreno M, Morales A, Guerra C, Navarro P, García de Frutos P.
PMID: 34973624
EBioMedicine. 2021 Dec 29;75:103797. doi: 10.1016/j.ebiom.2021.103797. Epub 2021 Dec 29.

BACKGROUND: Early diagnosis is crucial for patients with pancreatic ductal adenocarcinoma (PDAC). The AXL receptor tyrosine kinase is proteolytically processed releasing a soluble form (sAXL) into the blood stream. Here we explore the use of sAXL as a biomarker...

Cite
Martínez-Bosch N, Cristóbal H, Iglesias M, et al. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. EBioMedicine. 2021;75:103797doi: 10.1016/j.ebiom.2021.103797.
Martínez-Bosch, N., Cristóbal, H., Iglesias, M., Gironella, M., Barranco, L., Visa, L., Calafato, D., Jiménez-Parrado, S., Earl, J., Carrato, A., Manero-Rupérez, N., Moreno, M., Morales, A., Guerra, C., Navarro, P., & García de Frutos, P. (2021). Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. EBioMedicine, 75103797. https://doi.org/10.1016/j.ebiom.2021.103797
Martínez-Bosch, Neus, et al. "Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis." EBioMedicine vol. 75 (2021): 103797. doi: https://doi.org/10.1016/j.ebiom.2021.103797
Martínez-Bosch N, Cristóbal H, Iglesias M, Gironella M, Barranco L, Visa L, Calafato D, Jiménez-Parrado S, Earl J, Carrato A, Manero-Rupérez N, Moreno M, Morales A, Guerra C, Navarro P, García de Frutos P. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. EBioMedicine. 2021 Dec 29;75:103797. doi: 10.1016/j.ebiom.2021.103797. Epub 2021 Dec 29. PMID: 34973624; PMCID: PMC8724936.
Copy Download .nbib Format: NLM
Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study).

The American journal of cardiology

Alfonso F, Cuesta J, Ojeda S, Camacho-Freire S, García Del Blanco B, Vaquerizo B, Zueco J, Trillo R, Mauri J, Velázquez M, Córdoba-Soriano JG, Serra A, Navarro F, Pan M, Díaz J, Otaegui I, Salvatella N, De la TorreHernandez JM, Val DD, Bastante T, Rivero F.
PMID: 34903344
Am J Cardiol. 2022 Jan 01;162:31-40. doi: 10.1016/j.amjcard.2021.09.027.

Currently, both drug-eluting stents (DES) and drug-eluting balloons are recommended in patients with in-stent restenosis (ISR) of metallic stents. However, the clinical results of repeated interventions in patients with restenosis of bioresorbable vascular scaffolds (BVS) remain unsettled. We sought...

Cite
Alfonso F, Cuesta J, Ojeda S, et al. Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study). Am J Cardiol. 2022;162:31-40doi: 10.1016/j.amjcard.2021.09.027.
Alfonso, F., Cuesta, J., Ojeda, S., Camacho-Freire, S., García Del Blanco, B., Vaquerizo, B., Zueco, J., Trillo, R., Mauri, J., Velázquez, M., Córdoba-Soriano, J. G., Serra, A., Navarro, F., Pan, M., Díaz, J., Otaegui, I., Salvatella, N., De la TorreHernandez, J. M., Val, D. D., Bastante, T., Rivero, F. (2022). Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study). The American journal of cardiology, 16231-40. https://doi.org/10.1016/j.amjcard.2021.09.027
Alfonso, Fernando, et al. "Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study)." The American journal of cardiology vol. 162 (2022): 31-40. doi: https://doi.org/10.1016/j.amjcard.2021.09.027
Alfonso F, Cuesta J, Ojeda S, Camacho-Freire S, García Del Blanco B, Vaquerizo B, Zueco J, Trillo R, Mauri J, Velázquez M, Córdoba-Soriano JG, Serra A, Navarro F, Pan M, Díaz J, Otaegui I, Salvatella N, De la TorreHernandez JM, Val DD, Bastante T, Rivero F. Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study). Am J Cardiol. 2022 Jan 01;162:31-40. doi: 10.1016/j.amjcard.2021.09.027. PMID: 34903344.
Copy Download .nbib Format: NLM
Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents.

Journal of cutaneous pathology

Navarro R, Delgado-Jiménez Y, Guinea-Viniegra J, Llamas-Velasco M, Daudén E.
PMID: 34322902
J Cutan Pathol. 2021 Jul 28; doi: 10.1111/cup.14113. Epub 2021 Jul 28.

BACKGROUND: Expression of microRNA-21 (miR-21) is increased in psoriasis, leading to reduced levels of epidermal tissue inhibitor of matrix metalloproteinase 3 (TIMP-3), a highly potent inhibitor of the tumor necrosis factor alpha (TNFα) sheddase TACE (TNFα-converting enzyme)/ADAM17. We described...

Cite
Navarro R, Delgado-Jiménez Y, Guinea-Viniegra J, et al. Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents. J Cutan Pathol. 2021;doi: 10.1111/cup.14113.
Navarro, R., Delgado-Jiménez, Y., Guinea-Viniegra, J., Llamas-Velasco, M., & Daudén, E. (2021). Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents. Journal of cutaneous pathology, . https://doi.org/10.1111/cup.14113
Navarro, Raquel, et al. "Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents." Journal of cutaneous pathology vol. (2021). doi: https://doi.org/10.1111/cup.14113
Navarro R, Delgado-Jiménez Y, Guinea-Viniegra J, Llamas-Velasco M, Daudén E. Expression of microRNA-21 and TIMP-3 in paradoxical psoriasiform reactions during treatment with antitumor necrosis factor agents. J Cutan Pathol. 2021 Jul 28; doi: 10.1111/cup.14113. Epub 2021 Jul 28. PMID: 34322902.
Copy Download .nbib Format: NLM
The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre.

Brain communications

Delorme C, Houot M, Rosso C, Carvalho S, Nedelec T, Maatoug R, Pitron V, Gassama S, Sambin S, Bombois S, Herlin B, Ouvrard G, Bruneteau G, Hesters A, Gales AZ, Millet B, Lamari F, Lehericy S, Navarro V, Rohaut B, Demeret S, Maisonobe T, Yger M, Degos B, Mariani LL, Bouche C, Dzierzynski N, Oquendo B, Ketz F, Nguyen AH, Kas A, Lubetzki C, Delattre JY, Corvol JC.
PMID: 34401746
Brain Commun. 2021 Jun 17;3(3):fcab135. doi: 10.1093/braincomms/fcab135. eCollection 2021.

A variety of neuropsychiatric complications has been described in association with COVID-19 infection. Large scale studies presenting a wider picture of these complications and their relative frequency are lacking. The objective of our study was to describe the spectrum...

Cite
Delorme C, Houot M, Rosso C, et al. The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre. Brain Commun. 2021;3(3):fcab135doi: 10.1093/braincomms/fcab135.
Delorme, C., Houot, M., Rosso, C., Carvalho, S., Nedelec, T., Maatoug, R., Pitron, V., Gassama, S., Sambin, S., Bombois, S., Herlin, B., Ouvrard, G., Bruneteau, G., Hesters, A., Gales, A. Z., Millet, B., Lamari, F., Lehericy, S., Navarro, V., Rohaut, B., Demeret, S., Maisonobe, T., Yger, M., Degos, B., Mariani, L. L., Bouche, C., Dzierzynski, N., Oquendo, B., Ketz, F., Nguyen, A. H., Kas, A., Lubetzki, C., Delattre, J. Y., Corvol, J. C. (2021). The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre. Brain communications, 3(3), fcab135. https://doi.org/10.1093/braincomms/fcab135
Delorme, Cécile, et al. "The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre." Brain communications vol. 3,3 (2021): fcab135. doi: https://doi.org/10.1093/braincomms/fcab135
Delorme C, Houot M, Rosso C, Carvalho S, Nedelec T, Maatoug R, Pitron V, Gassama S, Sambin S, Bombois S, Herlin B, Ouvrard G, Bruneteau G, Hesters A, Gales AZ, Millet B, Lamari F, Lehericy S, Navarro V, Rohaut B, Demeret S, Maisonobe T, Yger M, Degos B, Mariani LL, Bouche C, Dzierzynski N, Oquendo B, Ketz F, Nguyen AH, Kas A, Lubetzki C, Delattre JY, Corvol JC. The wide spectrum of COVID-19 neuropsychiatric complications within a multidisciplinary centre. Brain Commun. 2021 Jun 17;3(3):fcab135. doi: 10.1093/braincomms/fcab135. eCollection 2021. PMID: 34401746; PMCID: PMC8344449.
Copy Download .nbib Format: NLM
Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes.

Molecular therapy. Methods & clinical development

Sevilla J, Navarro S, Rio P, Sánchez-Domínguez R, Zubicaray J, Gálvez E, Merino E, Sebastián E, Azqueta C, Casado JA, Segovia JC, Alberquilla O, Bogliolo M, Román-Rodríguez FJ, Giménez Y, Larcher L, Salgado R, Pujol RM, Hladun R, Castillo A, Soulier J, Querol S, Fernández J, Schwartz J, García de Andoín N, López R, Catalá A, Surralles J, Díaz-de-Heredia C, Bueren JA.
PMID: 34485595
Mol Ther Methods Clin Dev. 2021 Jun 12;22:66-75. doi: 10.1016/j.omtm.2021.06.001. eCollection 2021 Sep 10.

Difficulties in the collection of hematopoietic stem and progenitor cells (HSPCs) from Fanconi anemia (FA) patients have limited the gene therapy in this disease. We have investigated (ClinicalTrials.gov, NCT02931071) the safety and efficacy of filgrastim and plerixafor for mobilization...

Cite
Sevilla J, Navarro S, Rio P, et al. Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Mol Ther Methods Clin Dev. 2021;22:66-75doi: 10.1016/j.omtm.2021.06.001.
Sevilla, J., Navarro, S., Rio, P., Sánchez-Domínguez, R., Zubicaray, J., Gálvez, E., Merino, E., Sebastián, E., Azqueta, C., Casado, J. A., Segovia, J. C., Alberquilla, O., Bogliolo, M., Román-Rodríguez, F. J., Giménez, Y., Larcher, L., Salgado, R., Pujol, R. M., Hladun, R., Castillo, A., Soulier, J., Querol, S., Fernández, J., Schwartz, J., García de Andoín, N., López, R., Catalá, A., Surralles, J., Díaz-de-Heredia, C., & Bueren, J. A. (2021). Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Molecular therapy. Methods & clinical development, 2266-75. https://doi.org/10.1016/j.omtm.2021.06.001
Sevilla, Julián, et al. "Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes." Molecular therapy. Methods & clinical development vol. 22 (2021): 66-75. doi: https://doi.org/10.1016/j.omtm.2021.06.001
Sevilla J, Navarro S, Rio P, Sánchez-Domínguez R, Zubicaray J, Gálvez E, Merino E, Sebastián E, Azqueta C, Casado JA, Segovia JC, Alberquilla O, Bogliolo M, Román-Rodríguez FJ, Giménez Y, Larcher L, Salgado R, Pujol RM, Hladun R, Castillo A, Soulier J, Querol S, Fernández J, Schwartz J, García de Andoín N, López R, Catalá A, Surralles J, Díaz-de-Heredia C, Bueren JA. Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Mol Ther Methods Clin Dev. 2021 Jun 12;22:66-75. doi: 10.1016/j.omtm.2021.06.001. eCollection 2021 Sep 10. PMID: 34485595; PMCID: PMC8390450.
Copy Download .nbib Format: NLM
Showing 1921 to 1925 of 1925 entries